Hank Greely discusses recent attempts to introduce FMRI-based lie detection as courtroom evidence; Jake Sherkow analyzes a recent appellate court decision about "pay to delay" settlements between name brand drug companies and generic manufacturers; and Matt Lamkin argues against proposals to expand regulatory oversight of "enhancement" technologies. (September 13, 2012)